Secondary Pancreatic Diabetes
Conditions
Keywords
Closed-loop insulin delivery systems, artificial pancreas, pancreatitis, pancreatectomy, secondary diabetes, continuous glucose monitoring
Brief summary
The purpose of this study is to evaluate the metabolic and the safety outcomes in people living with pancreatic diabetes (pancreatitis or pancreatectomy-induced diabetes) and using a closed-loop insulin delivery systems (artificial pancreas).
Detailed description
Secondary pancreatic diabetes is an unstable diabetes, due to deficiency in B cells which produce insulin, alpha cells which produce glucagon, and exorcrine insufficiency. Patients with secondary pancreatic diabetes are exposed to high glycemic variability and severe hypoglycemic episodes. Hybrid closed loop treatment has shown efficacy and safety for patients with type 1 diabetes and has the potential to improve the control of secondary pancreatic diabetes but has rarely been studied in this particular indication. A retrospective observational cohort study in patients will be contucted suffering from secondary pancreatic diabetes in whom this device was implemented in order to observe metabolic and safety outcomes compared to the period before they were treated with hybrid closed-loop system.
Interventions
Patients with secondary pancreatic diabetes equipped with a hybrid closed loop insulin delivery device
Sponsors
Centre Hospitalier Sud Francilien
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patient * Presenting secondary pancreatic diabetes * Treatment with insulin closed-loop delivery
Exclusion criteria
* Patient who objected to the use of data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of time spent in the target | at day 0 | Percentage of time spent in the target, between 70 and 180 mg/dl: 14 to 90 days before starting hybrid closed loop |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pourcentage of closed-loop mode use | at day 90 | Pourcentage of closed-loop mode use |
| Hypoglycemia events (serveral hypoglycemia ) | at day 0 | Number of serveral hypoglycemia events requiring hospitilisation and/or emergency |
| Hyperglycemia events | at day 0 | Number of hyperglycemia events requiring hospitalisation and /or emergency |
| Percentage of time spent | at day 0 | Percentage of time spent bellow 70 mg/dL (TBR for Time Bellow Range ) and Above 180 mg/dL (TAR for Time Above Range ) |
| Coeffecient of variabilty of Glucose Management Indicator | at day 0 | Coeffecient of variabilty |
| Microangiopathic events | at day 0 | Number of microangiopathic events (diabetic retinopathy ,diabetic nephropathy, diabetic neuropathy ) |
| Glucose Management Indicator (GMI) | at day 0 | Glucose Management Indicator (GMI) |
Countries
France
Outcome results
None listed